Melatonine Glenmark

Melatonin, the active ingredient in Melatonine Glenmark, is a melatonin receptor agonist presented as an oral dosage form for oral use. It is employed to manage insomnia and sleep‑wake rhythm disorders in adults. The product is manufactured to EU standards and is distributed as a regulated pharmaceutical preparation.

GNH USA supplies Melatonine Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Melatonine Glenmark, a melatonin receptor agonist, is indicated for disorders of the sleep‑wake cycle.

Insomnia: helps initiate and maintain sleep in adults. Sleep‑wake rhythm disorders: assists in aligning circadian rhythm to a normal pattern. Delayed sleep phase disorder: promotes earlier sleep onset and improves daytime alertness.

Melatonine Glenmark may cause a range of adverse reactions. Most are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: transient feeling of light‑headedness. - Daytime sleepiness: occasional residual drowsiness. - Nausea: mild gastrointestinal upset. - Abdominal discomfort: mild stomach pain.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling of face or throat. - Mood changes: depression or irritability. - Severe dizziness or vertigo. - Hallucinations or vivid dreams. - Rare cardiac arrhythmias. - Severe hypersensitivity: anaphylaxis.

Before using Melatonine Glenmark, consider the following safety measures.

Pregnancy: consult a healthcare provider; safety not established. Breastfeeding: advise caution; potential transfer to milk. Elderly: start with the lowest effective dose and monitor for excessive sedation. Concomitant CNS depressants: may increase drowsiness; adjust therapy as needed. Driving or operating machinery: avoid if residual sleepiness persists. Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Melatonine Glenmark can interact with other medicines; review the following categories.

Major Interactions (Avoid): - Other melatonin agonists: risk of excessive sedation. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise melatonin plasma levels. - Anticoagulants (e.g., warfarin): potential increase in bleeding risk.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, antihistamines): may enhance drowsiness. - Immunosuppressants (cyclosporine, tacrolimus): possible reduction in immunosuppressant efficacy.